Rubertis Francesco De Net Worth

The estimated Net Worth of Rubertis Francesco De is at least $22 Milion dollars as of 10 August 2016. Rubertis De owns over 1,000,000 units of Minerva Neurosciences Inc stock worth over $11,983,686 and over the last 10 years Rubertis sold NERV stock worth over $10,000,000.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Rubertis De NERV stock SEC Form 4 insiders trading

Rubertis has made over 3 trades of the Minerva Neurosciences Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Rubertis sold 1,000,000 units of NERV stock worth $10,000,000 on 10 August 2016.

The largest trade Rubertis's ever made was buying 1,620,833 units of Minerva Neurosciences Inc stock on 7 July 2014 worth over $9,724,998. On average, Rubertis trades about 705,867 units every 191 days since 2014. As of 10 August 2016 Rubertis still owns at least 4,488,272 units of Minerva Neurosciences Inc stock.

You can see the complete history of Rubertis De stock trades at the bottom of the page.

What's Rubertis De's mailing address?

Rubertis's mailing address filed with the SEC is C/O MINERVA NEUROSCIENCES, INC., 245 FIRST STREET, SUITE 1800, CAMBRIDGE, MA, 02142.

Insiders trading at Minerva Neurosciences Inc

Over the last 10 years, insiders at Minerva Neurosciences Inc have traded over $49,043,620 worth of Minerva Neurosciences Inc stock and bought 8,182,692 units worth $47,876,311 . The most active insiders traders include & Johnson Johnson & Johnson..., Venture Associates Iii Ltd ... a Capital Iii Llc Care Capita.... On average, Minerva Neurosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $556,476. The most recent stock trade was executed by Remy Luthringer on 28 April 2023, trading 27,394 units of NERV stock currently worth $105,193.

What does Minerva Neurosciences Inc do?

minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its

Complete history of Rubertis De stock trades at Minerva Neurosciences Inc

Minerva Neurosciences Inc executives and stock owners

Minerva Neurosciences Inc executives and other stock owners filed with the SEC include:

• Michael Davidson,
  Chief Medical Officer
• Devin Smith,
  Senior Vice President, General Counsel
• Remy Luthringer,
  Chief Executive Officer and Executive Chairman of the Board of Directors
• Geoffrey Race,
  Executive Vice President, Chief Financial Officer and Chief Business Officer
• Dr. Remy Luthringer Ph.D.,
  Exec. Chairman & CEO
• Frederick Ahlholm,
  Senior Vice President, Chief Accounting Officer
• Dr. Rémy Luthringer,
  Exec. Chairman & CEO
• Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBA,
  Pres
• Dr. Jay B. Saoud Ph.D.,
  Consultant
• William Doyle,
  Lead Independent Director
• Jan van Heek,
  Independent Director
• Jeryl Hilleman,
  Independent Director
• Hans Hasler,
  Independent Director
• David Kupfer,
  Independent Director
• Fouzia Laghrissi-Thode,
  Independent Director
• William Boni,
  IR Contact Officer
• Jay Saoud,
  Senior Vice President, Head of Research and Development
• Joseph Reilly,
  Chief Operating Officer, Senior Vice President
• Dr. Ramana Kuchibhatla Ph.D.,
  Sr. VP and Head of R&D
• Dr. Michael Davidson M.D.,
  Chief Medical Officer
• Joseph Reilly,
  Sr. VP & COO
• Frederick W. Ahlholm CPA, CPA,
  Chief Financial Officer
• William B. Boni,
  VP of Investor Relations & Corp. Communications
• Marc D Beer,
  Director
• Mark S. Levine,
  SVP,General Counsel & Sec.
• Michele Ollier,
  Director
• Venture Associates Iii Ltd ...,
  
• Nico Vandervelpen,
  Director
• Rubertis Francesco De,
  Director
• Richard E. Russell,
  President
• & Johnson Johnson & Johnson...,
  
• Capital Iii Llc Care Capita...,
  
• Coelho Rogerio Vivaldi,
  President and CEO
• Lorenzo Pellegrini,
  Director
• Geoff Race,
  President
• Plc Barclays,
  10% owner